Altace Will Provide "Stable" Growth Platform For Three Years, King Says
This article was originally published in The Pink Sheet Daily
Executive Summary
King plans to tap the ACE inhibitor's market potential through expanded indications and inclusion of ramipril on hospital discharge protocols, Corporate Head of Commercial Operations Andrzejewski says. The company is targeting the second half of 2005 for NDA filings in pediatric hypertension and chronic kidney disease.
You may also be interested in...
Cobalt's Altace Generic Gets FDA Approval, 180 Days Of Exclusivity
King and Cobalt appear to be in settlement talks over ongoing patent litigation in Boston federal court.
Cobalt's Altace Generic Gets FDA Approval, 180 Days Of Exclusivity
King and Cobalt appear to be in settlement talks over ongoing patent litigation in Boston federal court.
Altace Will See Challenge From Generic ACE Inhibitors, Not Class Labeling, King Says
Increased attention to benefits of antihypertensives will help Altace and the entire class, King says. “We just have to fight the...battle” on differentiation, CEO Markison says.